Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02111798 · ClinicalTrials.gov registry record · Phase 2
Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT02111798: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT02111798 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02111798, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
This project will examine effects of bupropion extended release (XL) at a dose of 300mg/day for cocaine abstinence among persons receiving methadone for the treatment of opioid use disorder. Participants also earned financial incentives for providing urine samples that tested negative for cocaine. Bupropion was examined for this purpose because of its previously demonstrated efficacy and safety as well as its pharmacological actions at dopamine systems. Participants were randomly assigned to bupropion XL vs. placebo and received different incentive schedules depending on whether they demonstrated abstinence from cocaine early in the study. Outcomes were tracked over a 6-month time frame and the overarching hypothesis was that bupropion (as compared to placebo) would increase the number of urine samples testing negative for cocaine, independent of whether participants demonstrated abstinence from cocaine early in the study.
Interventions
- DRUG Placebo
- BEHAVIORAL Relapse Prevention
- DRUG Bupropion XL
- BEHAVIORAL Abstinence Initiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2014-07 |
| Est. Completion | 2021-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02111798
The ClinicalTrials.gov registry entry for NCT02111798 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02111798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02111798 about?
NCT02111798 is a clinical study titled "Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence". This project will examine effects of bupropion extended release (XL) at a dose of 300mg/day for cocaine abstinence among persons receiving methadone for the treatment of opioid use disorder. Participants also earned financial incentives for providing urine samples that tested negative for cocaine. B...
What is the current status of trial NCT02111798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2014-07. Estimated completion is 2021-01.
What interventions are being tested in trial NCT02111798?
The interventions under investigation include: Placebo (DRUG), Relapse Prevention (BEHAVIORAL), Bupropion XL (DRUG), Abstinence Initiation (BEHAVIORAL).
Who is sponsoring clinical trial NCT02111798?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.